Natco Pharma stock corrected sharply due to weak Q3 results, but future opportunities like semaglutide offer hope.
Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...
Criminals are targeting pharmacies and stealing weight-loss medication in a country with body image insecurities and where ...
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...
Most Americans would prefer brand-name drugs—but end up buying generic versions because of the cost, new consumer research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback